{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:39Z","timestamp":1740144099749,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T00:00:00Z","timestamp":1621123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T00:00:00Z","timestamp":1621123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40268-021-00346-3","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T09:02:20Z","timestamp":1621155740000},"page":"217-229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population Pharmacokinetic Analysis of Rivipansel in Healthy Subjects and Subjects with Sickle Cell Disease"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7225-1317","authenticated-orcid":false,"given":"Satyaprakash","family":"Nayak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0423-1856","authenticated-orcid":false,"given":"Brinda","family":"Tammara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-1577","authenticated-orcid":false,"given":"Lutz O.","family":"Harnisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,16]]},"reference":[{"key":"346_CR1","unstructured":"Centers for Disease Control and Prevention. Data and statistics on sickle cell disease (SCD). 2019. https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html. Accessed 21 Jul 2020."},{"key":"346_CR2","first-page":"40","volume":"112","author":"H Davis","year":"1997","unstructured":"Davis H, Moore JRRM, Gergen PJ. Cost of hospitalizations associated with sickle cell disease in the United States. Public Health Rep. 1997;112:40\u20133.","journal-title":"Public Health Rep."},{"key":"346_CR3","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.1016\/S2352-3026(20)30036-3","volume":"7","author":"BPD Inusa","year":"2020","unstructured":"Inusa BPD, Stewart CE, Mathurin-Charles S, et al. Paediatric to adult transition care for patients with sickle cell disease: a global perspective. Lancet Haematol. 2020;7:e329\u201341.","journal-title":"Lancet Haematol."},{"key":"346_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.blre.2013.09.001","volume":"27","author":"J Kanter","year":"2013","unstructured":"Kanter J, Kruse-Jarres R. Management of sickle cell disease from childhood through adulthood. Blood Rev. 2013;27:279\u201387.","journal-title":"Blood Rev."},{"key":"346_CR5","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","volume":"330","author":"OS Platt","year":"1994","unstructured":"Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639\u201344.","journal-title":"N Engl J Med."},{"key":"346_CR6","first-page":"4","volume":"15","author":"SL Saraf","year":"2014","unstructured":"Saraf SL, Molokie RE, Nouraie M, et al. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev. 2014;15:4\u201312.","journal-title":"Paediatr Respir Rev."},{"key":"346_CR7","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","volume":"122","author":"D Manwani","year":"2013","unstructured":"Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013;122:3892\u20138.","journal-title":"Blood"},{"key":"346_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","volume":"390","author":"RE Ware","year":"2017","unstructured":"Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390:311\u201323.","journal-title":"Lancet"},{"key":"346_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1203\/00006450-199602000-00001","volume":"39","author":"A Etzioni","year":"1996","unstructured":"Etzioni A. Adhesion molecules: their role in health and disease. Pediatr Res. 1996;39:191\u20138.","journal-title":"Pediatr Res."},{"key":"346_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/cpdd.842","volume":"9","author":"BK Tammara","year":"2020","unstructured":"Tammara BK, Ryan K, Plotka A, et al. Effect of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of intravenous rivipansel. Clin Pharmacol Drug Dev. 2020;9:918\u201328.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"346_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/psp4.12263","volume":"6","author":"BK Tammara","year":"2017","unstructured":"Tammara BK, Harnisch LO. Dose selection based on modeling and simulation for rivipansel in pediatric patients aged 6 to 11 years with sickle cell disease. CPT Pharmacomet Syst Pharmacol. 2017;6:845\u201354.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"346_CR12","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood-2014-06-583351","volume":"125","author":"MJ Telen","year":"2015","unstructured":"Telen MJ, Wun T, McCavit TL, et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood. 2015;125:2656\u201364.","journal-title":"Blood"},{"key":"346_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.5581\/1516-8484.20130107","volume":"35","author":"RP de Paula","year":"2013","unstructured":"de Paula RP, Nascimento AF, Sousa SM, Bastos PR, Barbosa AA. Glomerular filtration rate is altered in children with sickle cell disease: a comparison between Hb SS and Hb SC. Rev Bras Hematol Hemoter. 2013;35:349\u201351.","journal-title":"Rev Bras Hematol Hemoter."},{"key":"346_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2215\/CJN.08511109","volume":"5","author":"JP Haymann","year":"2010","unstructured":"Haymann JP, Stankovic K, Levy P, et al. Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature. Clin J Am Soc Nephrol. 2010;5:756\u201361.","journal-title":"Clin J Am Soc Nephrol."},{"key":"346_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/ckj\/sfx027","volume":"10","author":"V Audard","year":"2017","unstructured":"Audard V, Bartolucci P, Stehle T. Sickle cell disease and albuminuria: recent advances in our understanding of sickle cell nephropathy. Clin Kidney J. 2017;10:475\u20138.","journal-title":"Clin Kidney J."},{"key":"346_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jpeds.2009.06.060","volume":"156","author":"RE Ware","year":"2010","unstructured":"Ware RE, Rees RC, Sarnaik SA, et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr. 2010;156:66\u201370.","journal-title":"J Pediatr."},{"key":"346_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ajh.23365","volume":"88","author":"B Aygun","year":"2013","unstructured":"Aygun B, Mortier NA, Smeltzer MP, Shulkin BL, Hankins JS, Ware RE. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol. 2013;88:116\u20139.","journal-title":"Am J Hematol."},{"key":"346_CR18","unstructured":"Dampier CD, Telen MJ, Wun T, et al. Efficacy and safety of rivipansel (GMI-1070) in the treatment of vaso-occlusive crisis in hospitalized patients with sickle cell disease: results from the RESET phase 3 study [abstract]. Presented at: Annual Sickle Cell Disease Research and Educational Symposium and National Sickle Cell Disease Scientific Meeting; 23\u201325 September 2020."},{"key":"346_CR19","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/jcph.924","volume":"57","author":"BK Tammara","year":"2017","unstructured":"Tammara BK, Plotka A, Shafer FE, Readett DRJ, Riley S, Korth-Bradley JM. Lack of effect of rivipansel on QTc interval in healthy adult African American male subjects. J Clin Pharmacol. 2017;57:1315\u201321.","journal-title":"J Clin Pharmacol."},{"key":"346_CR20","doi-asserted-by":"publisher","first-page":"e101301","DOI":"10.1371\/journal.pone.0101301","volume":"9","author":"T Wun","year":"2014","unstructured":"Wun T, Styles L, DeCastro L, et al. Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia. PLoS ONE. 2014;9:e101301.","journal-title":"PLoS ONE"},{"key":"346_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med."},{"key":"346_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629\u201337.","journal-title":"J Am Soc Nephrol."},{"key":"346_CR23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"17","author":"D DuBois","year":"1916","unstructured":"DuBois D, DuBois EF. Clinical calorimetry tenth paper a formula to estimate the approximate surface area if height and weight be known. Arch Intern Med (Chic). 1916;17:863\u201371.","journal-title":"Arch Intern Med (Chic)."},{"key":"346_CR24","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","volume":"53","author":"AS Levey","year":"2007","unstructured":"Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766\u201372.","journal-title":"Clin Chem."},{"key":"346_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"346_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/psp4.12422","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ. NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacomet Syst Pharmacol. 2019;8:538\u201356.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"346_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1365-2885.2004.00600.x","volume":"27","author":"PL Toutain","year":"2004","unstructured":"Toutain PL, Bousquet-Melou A. Plasma terminal half-life. J Vet Pharmacol Ther. 2004;27:427\u201339.","journal-title":"J Vet Pharmacol Ther."},{"key":"346_CR28","unstructured":"Bauer RJ. NONMEM users guide: introduction to NONMEM 7.4.1. Gaithersburg (MD): ICON Development Soluitons; 2017."},{"key":"346_CR29","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. 2020. https:\/\/www.r-project.org\/. Accessed 5 May 2020."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00346-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-021-00346-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00346-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T05:09:19Z","timestamp":1623733759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-021-00346-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,16]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["346"],"URL":"https:\/\/doi.org\/10.1007\/s40268-021-00346-3","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2021,5,16]]},"assertion":[{"value":"12 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Satyaprakash Nayak, Brinda Tammara, and Lutz O. Harnisch are employees of Pfizer and may own stock\/options in the company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All studies included in this analysis were approved by an institutional review board or ethics committee at each study center and were conducted in accordance with the principles of the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice guidelines, and local regulatory requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"In all studies, all patients provided written informed consent prior to participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Upon request, and subject to certain criteria, conditions, and exceptions (see\u00a0 for more information), Pfizer will provide access to individual de-identified\u00a0participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the USA and\/or European Union or (2) in programs that have been terminated (i.e., development for all indications has been discontinued).\u00a0Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan.\u00a0Data may be requested from Pfizer trials 24 months after study completion.\u00a0The de-identified\u00a0participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"All authors contributed to the study conception and design. All authors collaborated in the preparation of the manuscript, with editorial support funded by Pfizer Inc., and critically reviewed and provided revisions to the manuscript. All authors had access to the data and assume responsibility for the completeness and accuracy of the data and data analyses. All authors granted final approval of the manuscript for submission.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}